INT57719

Context Info Confidence 0.44 First Reported 1993 Last Reported 2007 Negated 2 Speculated 1 Reported most in Abstract Documents 7 Total Number 8 Disease Relevance 0.95 Pain Relevance 5.97

Anatomy Link Frequency liver 2 plasma 1 SH-SY5Y 1 muscle tissue 1 muscles 1 GPM6A (Homo sapiens)

Pain Link Frequency Relevance Heat Morphine 71 100.00 noradrenaline 3 99.98 narcan 9 99.66 opiate 9 98.52 Bioavailability 1 98.20 opioid receptor 2 89.20 Opioid receptor 1 6 88.88 Analgesic 4 82.40 Pain 2 75.00 Opioid 2 75.00

Disease Link Frequency Relevance Heat Neuroblastoma 1 97.64 Cirrhosis 110 95.44 Pain 1 75.00 Helminth Infection 2 74.76 Hyperalgesia 1 25.00 Neuropathic Pain 1 25.00 Myoclonus 1 25.00 Disease 7 23.12 Apoptosis 13 5.00 Fibrosis 8 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

M3G and M6G are formed by morphine glucuronidation, mainly in the liver, and are excreted by the kidneys.

Localization (excreted) of M6G in liver associated with morphine

1) Confidence 0.44 Published 2003 Journal J Pain Symptom Manage Section Abstract Doc Link 12565191 Disease Relevance 0.07 Pain Relevance 1.15

Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance.

Localization (form) of M6G in plasma associated with morphine

2) Confidence 0.19 Published 1993 Journal Clin Pharmacokinet Section Abstract Doc Link 8491060 Disease Relevance 0 Pain Relevance 0.92

However, naloxone could not block M6G stimulated NO release by muscle tissue, whereas CTOP (10(-7) M) blocked its release.

Neg (NO) Localization (release) of M6G in muscle tissue associated with narcan

3) Confidence 0.13 Published 2004 Journal Acta. Biol. Hung. Section Abstract Doc Link 15270252 Disease Relevance 0.07 Pain Relevance 1.21

We have examined the opiate binding characteristics, effects on cAMP formation and [3H]noradrenaline release of morphine, morphine-6 (M6G) and -3 (M3G)-glucuronides, and fentanyl in SH-SY5Y human neuroblastoma cells.

Localization (release) of M6G in SH-SY5Y associated with neuroblastoma, noradrenaline, opiate and morphine

4) Confidence 0.10 Published 1993 Journal Biochem. Pharmacol. Section Abstract Doc Link 8216364 Disease Relevance 0.10 Pain Relevance 0.87

Nitric oxide (NO) release in various tissues in response to morphine and its metabolite morphine-6-glucuronide (M6G) were also examined.

Spec (examined) Localization (release) of M6G associated with morphine

5) Confidence 0.03 Published 2004 Journal J. Parasitol. Section Abstract Doc Link 15040662 Disease Relevance 0 Pain Relevance 0.76

However, naloxone could not block M6G-stimulated NO release by muscles, whereas CTOP (10(-7) M) blocked its release.

Neg (NO) Localization (release) of M6G in muscles associated with narcan

6) Confidence 0.03 Published 2004 Journal J. Parasitol. Section Abstract Doc Link 15040662 Disease Relevance 0 Pain Relevance 1.04

Of the M3G and M6G formed during a single passage, 19 +/- 11% and 9 +/- 9%, respectively, was excreted into bile; the values were significantly different (P = 0.002).

Localization (excreted) of M6G in bile

7) Confidence 0.03 Published 1997 Journal Pharm. Res. Section Body Doc Link 9279882 Disease Relevance 0 Pain Relevance 0

Fig. 4Immunohistochemical localization of 15dPGJ2-M6PHSA (a) and 15dPGJ2-pPBHSA (b) in liver of BDL-10d rats, 15 min after intravenous injection of the constructs.

Localization (localization) of M6PHSA in liver

8) Confidence 0.01 Published 2007 Journal Pharm Res Section Body Doc Link PMC1915609 Disease Relevance 0.70 Pain Relevance 0.03

General Comments

This test has worked.